Sign In
Buy ADPT
$22.57
-1.61 (-6.66%)
At Close: Jul 31, 2026
Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) CEO Sells $6,192,099.39 in Stock
04:21am, Monday, 16'th Mar 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) CEO Chad Robins sold 470,167 shares of the stock in a transaction dated Wednesday, March 11th. The shares were sold at an average
Allianz Asset Management GmbH Raises Stock Holdings in Adaptive Biotechnologies Corporation $ADPT
03:38am, Wednesday, 11'th Feb 2026
Allianz Asset Management GmbH boosted its position in shares of Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 305.8% in the third quarter, according to the company in its most recent filing w
Adaptive Biotechnologies Corporation (ADPT) Q4 2025 Earnings Call Transcript
12:14pm, Friday, 06'th Feb 2026
Adaptive Biotechnologies Corporation (ADPT) Q4 2025 Earnings Call Transcript
Chad Robins Sells 124,998 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock
04:40am, Friday, 06'th Feb 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) CEO Chad Robins sold 124,998 shares of the business's stock in a transaction dated Monday, February 2nd. The shares were sold at a
Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
08:30pm, Thursday, 05'th Feb 2026
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its k
Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Misses Revenue Estimates
06:35pm, Thursday, 05'th Feb 2026
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.23 per share a year ago.
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results
04:05pm, Thursday, 05'th Feb 2026
SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the gen
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
04:05pm, Tuesday, 27'th Jan 2026
SEATTLE, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026
04:05pm, Thursday, 22'nd Jan 2026
SEATTLE, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst
Adaptive Biotechnologies Corporation $ADPT Shares Bought by SG Americas Securities LLC
05:24am, Monday, 19'th Jan 2026
SG Americas Securities LLC increased its position in Adaptive Biotechnologies Corporation (NASDAQ: ADPT) by 82.5% in the third quarter, according to the company in its most recent Form 13F filing with
Adaptive Biotechnologies Corporation (ADPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
10:35pm, Monday, 12'th Jan 2026
Adaptive Biotechnologies Corporation (ADPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results
07:30am, Monday, 12'th Jan 2026
SEATTLE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syst
Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $164,400.00 in Stock
05:20am, Sunday, 11'th Jan 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) insider Harlan Robins sold 10,000 shares of the business's stock in a transaction on Tuesday, January 6th. The shares were sold at
Chad Robins Sells 124,998 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock
04:33am, Friday, 09'th Jan 2026
Adaptive Biotechnologies Corporation (NASDAQ: ADPT - Get Free Report) CEO Chad Robins sold 124,998 shares of the business's stock in a transaction dated Monday, January 5th. The stock was sold at an a
Adaptive Biotechnologies spinout raising $15M to develop clinical sequencing tech
11:51am, Tuesday, 06'th Jan 2026
Digital Biotechnologies Inc., a new Seattle-based subsidiary of publicly traded immune medicine company Adaptive Biotechnologies, has raised fresh cash as part of an initial closing of a Series A inve
